M&A

A Covid-19 threat to business acquisitions
A Covid-19 threat to business acquisitions
EP Vantage
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Flag link:
Mylan, Pfizer offer undisclosed concessions as part of EU merger review
Mylan, Pfizer offer undisclosed concessions as part of EU merger review
Fierce Pharma
Mylan
Pfizer
Upjohn
Europe
M&A
Flag link:
Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
Marketwatch
COVID-19
pandemic
clinical trials
drug launches
M&A
conferences
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link:
Pfizer, Mylan say COVID-19 delays will postpone their Viatris merger
Pfizer, Mylan say COVID-19 delays will postpone their Viatris merger
Fierce Pharma
COVID-19
Pfizer
Mylan
Viatris
M&A
Flag link:
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
BioSpace
AbbVie
Allergan
FTC
M&A
Flag link:
Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief
Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief
Endpoints
Bristol-Myers Squibb
M&A
Giovanni Caforio
Flag link:
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
Fierce Pharma
AbbVie
Allergan
FTC
M&A
COVID-19
Flag link:
Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap
Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap
Endpoints
antibiotics
Tetraphase
M&A
AcelRx
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Investors Business Daily
Gilead Scinecs
M&A
Forty Seven
immuno-oncology
Flag link:
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Fierce Biotech
Shionogi
Tetra Therapeutics
R&D
M&A
Flag link:
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Medical Marketing and Media
Bristol-Myers Squibb
Celgene
rebranding
M&A
Flag link:
AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match
AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match
Endpoints
AbbVie
Allergan
M&A
Flag link:
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Motley Fool
EXACT Sciences
M&A
diagnostics
cancer
Paradigm Diagnostics
Viomics
Flag link:
Thermo Fisher Scientific Set to Acquire Qiagen for $11.5B
Thermo Fisher Scientific Set to Acquire Qiagen for $11.5B
Medical Devices and Diagnostics Industry
ThermoFisher Scientific
Qiagen
M&A
diagnostics
Flag link:
Waksal's bid for Redx ends, forcing biotech to avert cash crunch
Waksal's bid for Redx ends, forcing biotech to avert cash crunch
Fierce Biotech
Redx
Sam Waksal
M&A
Flag link:
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Fierce Biotech
Gilead Sciences
M&A
Forty Seven
CD-47
Flag link:
BioPharma M&A Drives More Efficient Resource Allocation
BioPharma M&A Drives More Efficient Resource Allocation
Forbes
M&A
resource allocation
Flag link:
Medtronic Rumored to Be Looking at a Deal with LivaNova
Medtronic Rumored to Be Looking at a Deal with LivaNova
Medical Devices and Diagnostics Industry
Medtronic
devices
M&A
neuromodulation
LivaNova
Flag link:

Pages